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Abstract
Objective: Biochemical assessment is recommended for patients prior to initiating 
and following a ketogenic diet (KD). There is no published literature regarding cur-
rent practice in the UK and Ireland. We aimed to explore practice in comparison with 
international guidelines, determine approximate costs of biochemical testing in KD 
patients across the UK and Ireland, and promote greater consistency in KD services 
nationally.
Methods: A survey was designed to determine the biochemical tests requested for 
patients at baseline, 3, 6, 12, 18, and 24 months + on KD. The survey was circulated 
to 39 centers across the UK and Ireland.
Results: Sixteen centers completed the survey. Full blood count, electrolytes, cal-
cium, liver function tests (LFTs), lipid profile, and vitamin D were requested at 
all centers at baseline, in keeping with international guidelines. Bicarbonate, total 
protein, and urinalysis were less consistently requested. Magnesium and zinc were 
requested by all centers, despite not being specifically recommended for pre-diet 
evaluation in guidelines. Urea and electrolyte profiles and some LFTs were consist-
ently requested at follow-up, in accordance with guidelines. Other LFTs and renal 
tests, full blood count, lipid profile, acylcarnitine profile, selenium, vitamin D, and 
urinalysis were less consistently requested at follow-up. The mean costs of the lowest 
and highest number of tests requested at baseline in our participating centers were 
£167.54 and £501.93; the mean costs of the lowest and highest number of tests re-
quested at 3-month follow-up were £19.17 and £450.06.
Significance: Biochemical monitoring of KD patients varies widely across the UK 
and Ireland and does not fully correspond to international best practice guidelines. 
With an ongoing drive for cost-effectiveness within health care, further work is 
needed to streamline practice while ensuring patient safety.
K E Y W O R D S
high fat, laboratory, low carbohydrate
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1 |  INTRODUCTION
Ketogenic diets (KDs) are high-fat, low-carbohydrate, and 
moderate-protein diets used as a treatment option for drug-
resistant epilepsy. KDs are the treatment of choice for 
neurometabolic disorders such as glucose transport type 1 de-
ficiency syndrome1 and pyruvate dehydrogenase deficiency2 
and are effective in reducing seizure frequency in approxi-
mately one third of patients with epilepsy.3
Ketogenic diets are inappropriate for some individuals, 
for example, with primary carnitine deficiencies and β-ox-
idation defects, and thus, screening biochemical tests to 
rule out such disorders are a crucial part of pre-diet assess-
ment. KDs cause the body's metabolism to adjust, utilizing 
ketone bodies rather than glucose as its primary energy 
source. Due to stringent dietary restriction, individuals 
following a KD are often at risk of vitamin and mineral 
deficiencies,4,5 and therefore, close biochemical monitor-
ing is required to ensure nutritional adequacy and safety.
International consensus guidelines regarding optimal 
care of pediatric patients on KD therapies have been re-
cently updated, including which biochemical tests (blood 
and urine) should be completed prior to diet initiation 
and during the treatment period.6 These follow on from 
KD care guidelines for resource-limited countries pub-
lished in 2015, including required and desired biochemical 
monitoring.7
Over the past two decades, the number of KD services in 
the UK and Ireland has increased from 22 to 39, with a con-
comitant surge in the number of patients on diet (from 101 in 
20008 to 754 in 2017).9 Centers in the UK and Ireland have 
local guidance for biochemical assessment and monitoring 
for KD patients but, to date, there has been no comparison 
nor consolidation of existing practices. Many of the bio-
chemical tests required during KD treatment must be sent to 
specialist centers, further inflating costs and delays to treat-
ment, conflicting with the current climate of the National 
Health Service (NHS), where services aim to be clinically 
and cost-effective. The 2018 international recommendations 
involved a high proportion of non-UK healthcare profes-
sionals from countries where costs are paid by insurance or 
by the patient privately, which could lead to disparities in 
practice.
We aimed to (a) explore current practice of biochem-
ical testing in KD patients across the UK and Ireland in 
comparison with international guidelines, (b) determine 
approximate costs of biochemical testing in KD patients 
across the UK and Ireland, and (c) promote greater consis-
tency in KD services nationally. To our knowledge, this is 
the first investigation of its kind. It is hoped that this work 
will help determine adherence to guidelines with regards 
biochemical monitoring of patients with epilepsy following 
a KD in the UK and Ireland, and whether action needs to be 
taken to streamline practice while ensuring patient safety 
and financial benefit.
2 |  METHODS
A survey was designed by the Ketogenic Dietitians 
Research Network (KDRN) (a consortium of KD Healthcare 
Professionals) to identify biochemical tests requested in 
patients commencing and following a KD for epilepsy and 
metabolic disorders in centers in the UK and Ireland. The 
ketogenic dietitians at each center were asked to list all 
biochemical investigations requested at baseline (pre-diet), 
3, 6, 12, 18, and 24 months post-diet initiation during rou-
tine follow-up (and other time points if applicable), as well 
as the frequency of biochemical follow-up for patients on 
diet longer than two years (the point at which, routinely, 
patients and medical teams may consider discontinuing the 
diet). Centers were also invited to share the cost of each 
biochemical test requested as part of their KD service, if 
available, which provided an indication of the financial 
range anticipated for tests at both baseline and review.
The survey was disseminated via email to 39 services in 
the UK and Ireland. Following the initial email, two follow-up 
emails were sent in an attempt to obtain more responses. All 
answers were pseudo-anonymized, and results were com-
pared to the laboratory assessments recommended in interna-
tional best practice guidelines,6 as outlined in Table 1.
3 |  RESULTS
Sixteen centers completed the survey: 15 pediatric centers 
(of which 14 were NHS) and one non-NHS joint adult and 
pediatric center.
The number of patients referred annually for KD treat-
ment in each of these centers, the patient population (pediat-
rics or adults), and the type of center (primary, secondary, or 
tertiary care) are outlined in Table 2.
Key Points
• Baseline tests are mostly in keeping with interna-
tional guidelines, except for the addition of mag-
nesium and zinc
• Not all tests were not consistently requested by all 
centers at follow-up, despite recommendations
• Mean costs of baseline tests ranged from £167.54 
to £501.93
• Mean costs of 3-month follow-up tests ranged 
from £19.17 to £450.06
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3.1 | Current practice and comparison to 
international guidelines
A total of 63 different biochemical tests were requested across 
the participating centers. Table 3 outlines recommended tests, 
clustered into clinical groups, and lists which groups of tests 
were requested by all, by 90%-99%, by 75%-90%, by 50%-
75%, and then by <50% of participating centers. A list of all 
tests (ungrouped) and the percentage of centers that requested 
each test at each time point can be found in the Supplementary 
Table S1.
3.2 | Baseline monitoring
Full blood count, electrolytes, calcium, liver function tests 
(LFTs), lipid profile, and vitamin D were requested at all cent-
ers at baseline, in keeping with international guidelines (Table 
3). Bicarbonate, total protein, and urinalysis are recommended 
in international guidelines but were not consistently requested 
by our participating centers. Magnesium and zinc were also re-
quested by all centers, despite not being specifically mentioned 
for pre-diet evaluation in international guidelines.
3.3 | Follow-up monitoring
Twelve centers requested biochemical tests routinely at 3, 6, 
12, 18, and 24  months post-diet initiation; two centers did 
not request any tests at 3 months, one center that did not re-
quest any tests at 18 months, and one center requested tests at 
3 months and then 6-monthly thereafter (testing requested at 
3,9, and 15 months post-diet initiation).
Urea, creatinine and electrolytes, alanine aminotransferase 
(ALT), and alkaline phosphatase (ALP) were requested by all 
centers at 3-, 6-, 12-, 18-, and 24-month follow-up (centers 
T A B L E  1  Laboratory assessments recommended as part of pre-diet evaluation and follow-up visits in international best practice guidelines6
Laboratory assessment prior to ketogenic diet initiation Laboratory assessment during ketogenic diet treatment
Complete blood count with platelets Complete blood count with platelets
Electrolytes (including bicarbonate, total protein, calcium) Electrolytes (including bicarbonate, total protein, calcium)
Liver and kidney tests (including albumin, blood urea nitrogen, 
creatinine)
Liver and kidney profile (including albumin, blood urea nitrogen, creatinine)
Fasting lipid profile Fasting lipid profile
Serum acylcarnitine profile Free and total carnitine
Vitamin D level Vitamin D level
Urinalysis Urinalysis
Antiseizure drug levels (if applicable) Antiseizure drug levels (if applicable)
Urine organic acids (if diagnosis unclear) Selenium level
Amino acids (if diagnosis unclear) Optional
Beta-hydroxybutyrate (BOH) level
Urine calcium and creatinine
Zinc, copper levels
T A B L E  2  Key characteristics of participating centers
Center ID
Number of 
referrals 
(2016-17)a Patient population
Level of 
care
Center 1 9 Pediatrics Tertiary
Center 2 52 Pediatrics Tertiary
Center 3 17 Pediatrics Tertiary
Center 4 25 Adults Tertiary
Center 5 53 Pediatrics Tertiary
Center 6 76 Pediatrics Tertiary
Center 7 42 Pediatrics and adults Tertiary
Center 8 34 Pediatrics Tertiary
Center 9 45 Pediatrics Tertiary
Center 10 30 Pediatrics Tertiary
Center 11 17 Pediatrics Tertiary
Center 12 24 Pediatrics Tertiary
Center 13 23 Pediatrics Tertiary
Center 14 45 Pediatrics Tertiary
Center 15 18 Pediatrics Tertiary
Center 16 39 Pediatrics Tertiary
Center 17 12 Pediatrics Tertiary
Center 18 21 Adults Tertiary
Center 19 30 Pediatrics Tertiary
Center 20 7 Pediatrics Tertiary
Center 21 20 Pediatrics Tertiary
Center 22 6 Pediatrics Secondary
aFrom July 1, 2016, to June 30, 2017 (Whiteley et al10). 
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that routinely requested biochemical tests at these respective 
time points). Full blood count, lipid profile, and albumin 
were requested by each of our centers at every review except 
for the 18-month point. Other components of renal profile 
and liver function tests, acylcarnitine profile, selenium, vi-
tamin D, and urinalysis were less consistently requested at 
follow-up (Table 3).
13/16 (81%) centers requested non-fasting lipid profiles, 
both at baseline and review, despite recommendations for a 
fasting lipid profile. Seven of these 13 requested non-fasting 
lipid profiles, but would repeat in a fasted state if initial re-
sults were abnormal.
3.4 | Long-term follow-up
For those centers following patients up for more than 2 years: 
10/16 (63%) centers requested 6-monthly monitoring for pa-
tients following a KD, in keeping with guidelines advising 
6-monthly visits after following a KD for 1 year. 5/16 (33%) 
centers requested yearly monitoring and 1/16 (6%) had no 
protocol.
3.5 | Cost implications
The mean costs of the lowest and highest number of tests re-
quested at baseline in our participating centers were £167.54 
and £501.93; the mean costs of the lowest and highest num-
ber of tests requested at 3-month follow-up were £19.17 and 
£450.06. For comparison, the mean cost per visit of all bio-
chemical tests recommended in international guidelines was 
£108.96 at baseline and £126.09 at review. The minimum, 
maximum, and mean cost per test can be found in Table 4.
4 |  DISCUSSION
Our study illustrates that biochemical assessment and moni-
toring of KD patients with epilepsy vary widely across the 
UK and Ireland and do not fully correspond to international 
best practice guidelines.6 This variability is reflected in the 
associated costs of biochemistry testing. To our knowledge, 
there are no other previously published works outlining 
which biochemical tests are requested in KD patients in the 
UK and Ireland and their financial impact.
Variability of practice is inevitable, due to differing patient 
populations in each center and the acute needs of individuals, 
particularly in the complex cohort that commence dietary 
therapy for refractory epilepsy. However, the level of vari-
ability among our participating centers seems striking. This 
may be partially explained by the fact that the expansion of 
KD services in the UK and Ireland is a recent and somewhat TA
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sporadic phenomenon.9,10 Only in recent years have techno-
logical advances and the creation of national groups, such as 
KDRN, facilitated liaison across participatory centers, pro-
moting communication, and sharing of resources. Research 
study protocols, such as those from the original randomized 
controlled trial at Great Ormond Street11 and Ketogenic Diet 
in Infants with Epilepsy (KIWE),12 may also influence what 
tests are requested at participating centers.
Our costing results, although approximate, indicate that 
biochemical testing for KD patients can have a substantial 
financial impact on services, as well as highlighting the vari-
ability between centers. The final cost to an individual center 
will vary, as large teaching hospitals can often benefit from 
lower costings due to higher workload and are more likely to 
have specialist tests available on site. Between hospital lab-
oratories, the items included in a profile vary. In addition, 
the type of technology used (eg high-throughput minimal 
intervention automated analyzers versus mass spectrometry 
for 25-hydroxy vitamin D3) and, in some cases, the inter-
pretation of the laboratory price list can also impact the final 
cost: Some centers may ask for the cost to measure a set of 
electrolytes, liver function tests, and a bone profile, whereas 
asking for a “full profile” should cost slightly less due to the 
overlap in tests. Notwithstanding these caveats, a difference 
of £334.39 between minimum and maximum requested base-
line tests and £430.89 for 3-month review tests in our partic-
ipating centers is noteworthy.
Any “lesser” costs in KD laboratory monitoring need to be 
balanced against the possible increased risk of complications, 
with associated costs. Even the cost of “complete” KD mon-
itoring may be less than treatment with a new antiepileptic 
drug, which can cost up to approximately £100/month,13 as 
well as the costs implicated in seizure-related complications. 
On the other hand, it may not be appropriate to test for each 
recommended parameter at every review, such as vitamin D, 
due to the time taken for changes to take effect.14,15
Magnesium and zinc were requested by all our participat-
ing centers at baseline, despite not being included in inter-
national best practice guidelines for pre-diet evaluation. This 
may represent a cost saving if unnecessary in most patients. 
No report of zinc deficiencies in individuals following a KD 
has been identified, although classical KDs with a 2:1 ratio 
or higher fail to meet the dietary reference intake for zinc, 
despite “selection of nutrient dense foods”.16 One may argue 
that if mentioned as “optional” to measure at review, as in 
international guidelines, baseline assessment of zinc would 
also be appropriate. Mean plasma magnesium levels have 
been found to decrease in children on the classical KD,4 and 
the diet has been shown to provide suboptimal magnesium 
levels.16 Intakes of zinc and magnesium may be suboptimal 
even prior to KD initiation: 3%-27% and 0%-50% of the UK 
population surveyed in the latest National Diet and Nutrition 
Survey (including males and females across all age groups 
above 1.5  years) do not meet the lower reference nutrient 
intake (RNI) for zinc and magnesium, respectively.17
The discrepancies between which tests were requested 
at all review appointments in our centers compared to 
T A B L E  4  Minimum, maximum, and mean costs of biochemical 
tests in participating centers
Analyte(s)
Minimum 
(£)
Maximum 
(£) Mean (£)
Urea and Electrolytes 
(U/E)a
1.45 12 5.4
Bone profilea 0.99 12 4.88
Liver function Testsa 0.66 12 4.67
Lipid Profile 0.52 12 5.23
Beta-hydroxybutyrate 6.24 77.95 27.85
Magnesiuma 0.24 14.32 5.22
Zincb 7.13 21.4 13.06
Seleniumb 10 26.54 17.13
Copperb 7.13 14.32 11.15
Glucose 0.24 5.87 2.66
Acylcarnitine Profilec 32.24 100 69.8
Amino acid profilec 82 100 103.14
Urine calcium creatinine 
ratio
2.66 14.32 7.07
Full blood count (for Hb) 1.34 7.99 3.87
B12 2.35 14.32 7.54
Folate 2.49 12 6.26
Ferritin 2.09 12 5.77
Vitamin Ad 11.5 20.98 18.18
Vitamin Ed 11.5 20.98 18.18
25-hydroxy vitamin D3e 4.42 26.05 14.79
Clotting Screen 2.74 14.32 6.745
Urine Ketones (urine 
dipsticks)
0.11 0.26 0.315
Non-esterified fatty acids 77.95 77.95 £77.95
Acetoacetate 6.24 6.24 6.24
Thyroid function test 5.29 12 8.645
Amylase 4.63 4.63 £4.63
Urine organic acids 45.5 58.24 51.87
TOTAL £329.65 £710.68 £508.245
aThese components can be combined into a full profile, which may be lower cost 
than individual sets. 
bTrace elements may be able to be analyzed on a single sample in some centers, 
with a lower cost than the individual metals. 
cThese tests are only carried out at highly specialized laboratories and thus cost 
more due to limited availability and high degree of technical skill in carrying out 
the assay and interpreting the results. 
dVitamin A and E are usually analyzed together and should be at lower cost than 
when requested individually. 
eThe varied technology available to measure 25-hydroxy vitamin D3 greatly 
affects the cost of the test. 
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international recommendations may be predominantly cost-
driven, particularly considering that the 2018 guidelines in-
volved a high proportion of non-UK healthcare professionals 
from countries where costs are paid by insurance or by the 
patient privately, compared to the government-funded UK 
National Health Service, which could potentially be consid-
ered “resource-limited.” Furthermore, while NICE recom-
mends KDs for pediatric refractory epilepsy,18 it does not 
suggest recommendations for monitoring and so there is no 
UK cost-effective reference guidelines. In previous guide-
lines issued for resource-limited regions, bicarbonate was 
deemed mandatory at baseline and review, and urinalysis and 
lipid profile were mandatory at review.7
Published reports of abnormalities in individuals fol-
lowing KDs may provide guidance as to whether it is nec-
essary to request the “missing” parameters at each review 
in UK and Ireland centers. Besides dyslipidemia, which 
is one of the most well-cited (although often transient) 
biochemical side effects of KDs, occurring in approxi-
mately 12% of children studied prospectively on a KD,19 
reports of abnormalities of other parameters are uncom-
mon. Individuals following a KD have been shown to have 
reduced serum 25-hydroxyvitamin D concentration (as 
were individuals solely on antiepileptic drugs) and reduced 
bone mass (to a greater extent than in individuals solely 
on drug therapy)20; another study found 25-hydroxyvita-
min D levels (which were mostly low at diet initiation) 
to improve initially on commencement of a KD, includ-
ing supplementation, but to decline after three months.21 
Selenium deficiency has been reported in 66 individuals 
on KD treatment,22‒25 associated with cardiomyopathy in 
two of these patients23,25 and sudden cardiac death in an-
other two.24 A trend of decreasing plasma selenium was 
noted in participants of the original randomized controlled 
trial at GOSH, with a significant decrease between base-
line and six months in children on the classical KD, al-
though mean plasma selenium was maintained within the 
GOSH reference ranges.4
In view of the possible association of selenium with car-
diac abnormalities, monitoring of selenium seems signifi-
cant, although prolonged QT interval has also been reported 
in three cases following a KD in the absence of selenium de-
ficiency.26 The frequency of testing at review, particularly in 
the 12- to 24-month follow-up period, may need revisiting 
specifically for the UK and Ireland in order to balance clini-
cal safety with the potential financial/logistical constraints of 
6-monthly testing.
This study has several limitations. Only 16 of the 39 cen-
ters that (to our knowledge) practice KDs within the UK and 
Ireland volunteered to answer the survey; practice in the other 
centers remains unknown. The survey was not validated and 
could be subject to reporter error. Our cost estimations would 
also improve in accuracy with greater center participation. 
A follow-up study to assess whether rate of complications is 
correlated with frequency and “completeness” of laboratory 
monitoring would be pertinent.
Biochemical monitoring of KD patients varies widely 
across the UK and Ireland and does not fully correspond to 
international best practice guidelines. With an ongoing drive 
for cost-effectiveness within the NHS, further work is needed 
to streamline practice while ensuring patient safety, both for 
financial benefit without clinical compromise for patients, 
perhaps with the creation of nationwide-specific guidelines. 
Further research into biochemical monitoring of KDs world-
wide would be of interest to compare to practice in the UK 
and Ireland.
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